U.S. flag

An official website of the United States government

NM_000546.6(TP53):c.772G>A (p.Glu258Lys) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic/Likely pathogenic (3 submissions)
Last evaluated:
Nov 11, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000772122.11

Allele description [Variation Report for NM_000546.6(TP53):c.772G>A (p.Glu258Lys)]

NM_000546.6(TP53):c.772G>A (p.Glu258Lys)

Gene:
TP53:tumor protein p53 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17p13.1
Genomic location:
Preferred name:
NM_000546.6(TP53):c.772G>A (p.Glu258Lys)
Other names:
p.E258K:GAA>AAA
HGVS:
  • NC_000017.11:g.7674191C>T
  • NG_017013.2:g.18360G>A
  • NM_000546.6:c.772G>AMANE SELECT
  • NM_001126112.3:c.772G>A
  • NM_001126113.3:c.772G>A
  • NM_001126114.3:c.772G>A
  • NM_001126115.2:c.376G>A
  • NM_001126116.2:c.376G>A
  • NM_001126117.2:c.376G>A
  • NM_001126118.2:c.655G>A
  • NM_001276695.3:c.655G>A
  • NM_001276696.3:c.655G>A
  • NM_001276697.3:c.295G>A
  • NM_001276698.3:c.295G>A
  • NM_001276699.3:c.295G>A
  • NM_001276760.3:c.655G>A
  • NM_001276761.3:c.655G>A
  • NP_000537.3:p.Glu258Lys
  • NP_000537.3:p.Glu258Lys
  • NP_001119584.1:p.Glu258Lys
  • NP_001119585.1:p.Glu258Lys
  • NP_001119586.1:p.Glu258Lys
  • NP_001119587.1:p.Glu126Lys
  • NP_001119588.1:p.Glu126Lys
  • NP_001119589.1:p.Glu126Lys
  • NP_001119590.1:p.Glu219Lys
  • NP_001263624.1:p.Glu219Lys
  • NP_001263625.1:p.Glu219Lys
  • NP_001263626.1:p.Glu99Lys
  • NP_001263627.1:p.Glu99Lys
  • NP_001263628.1:p.Glu99Lys
  • NP_001263689.1:p.Glu219Lys
  • NP_001263690.1:p.Glu219Lys
  • LRG_321t1:c.772G>A
  • LRG_321:g.18360G>A
  • LRG_321p1:p.Glu258Lys
  • NC_000017.10:g.7577509C>T
  • NM_000546.4:c.772G>A
  • NM_000546.5:c.772G>A
  • P04637:p.Glu258Lys
Protein change:
E126K; GLU258LYS
Links:
UniProtKB: P04637#VAR_005991; OMIM: 191170.0002; dbSNP: rs121912652
NCBI 1000 Genomes Browser:
rs121912652
Molecular consequence:
  • NM_000546.6:c.772G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126112.3:c.772G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126113.3:c.772G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126114.3:c.772G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126115.2:c.376G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126116.2:c.376G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126117.2:c.376G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126118.2:c.655G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276695.3:c.655G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276696.3:c.655G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276697.3:c.295G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276698.3:c.295G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276699.3:c.295G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276760.3:c.655G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276761.3:c.655G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000905196Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Jan 14, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV001189203Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Nov 11, 2024)
germlineclinical testing

PubMed (11)
[See all records that cite these PMIDs]

Citation Link,

SCV002582357Genome-Nilou Lab
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Jun 18, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenonot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. Epub 2003 Jun 25.

PubMed [citation]
PMID:
12826609
PMCID:
PMC166245

Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

Frebourg T, Kassel J, Lam KT, Gryka MA, Barbier N, Andersen TI, Børresen AL, Friend SH.

Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6413-7.

PubMed [citation]
PMID:
1631137
PMCID:
PMC49511
See all PubMed Citations (12)

Details of each submission

From Color Diagnostics, LLC DBA Color Health, SCV000905196.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This missense variant replaces glutamic acid with lysine at codon 258 in the DNA binding domain of the TP53 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that the mutant protein to be non-functional and exhibit dominant negative effect in transactivation assays (PMID: 12826609, 16492679, 20128691, 21343334) and in cell growth assays (PMID: 29979965, 30224644). This variant has been reported in individuals affected with Li-Fraumeni syndrome (PMID: 9667734, 10922393, 1978757, 21552135). This variant has been identified in 1/246228 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Ambry Genetics, SCV001189203.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (11)

Description

The p.E258K pathogenic mutation (also known as c.772G>A), located in coding exon 6 of the TP53 gene, results from a G to A substitution at nucleotide position 772. The glutamic acid at codon 258 is replaced by lysine, an amino acid with similar properties. The p.E258K variant was first reported in a patient diagnosed with breast cancer at 34 whose tumor demonstrated loss of heterozygosity (LOH), and whose family met classic LFS criteria with a history of early onset sarcomas, and brain tumors (Malkin D et al. Science. 1990 Nov;250:1233-8). This variant has also been reported in a family with a strong history of gastric cancers, and in an individual with glioblastoma multiforme (Masciari S et al. Genet. Med. 2011 Jul;13:651-7; Huang KL et al. Cell, 2018 04;173:355-370.e14). Yeast based functional studies showed this alteration to have loss of transactivation capacity, and dominant negative effect (IARC TP53 database; Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9; Monti P et al. Mol. Cancer Res. 2011 Mar;9:271-9). Studies on this variant conducted in mammalian cells showed inability to suppress growth, and a protein binding profile indicative of a mutant protein conformation (Frebourg T et al. Proc. Natl. Acad. Sci. U.S.A., 1992 Jul;89:6413-7). Additional studies conducted in human cell lines also indicate this alteration is deficient at growth suppression and has a dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This alteration has been observed numerous times as a somatic mutation in the cancerhotspots.org database (Chang MT et al. Cancer Discov. 2018 02;8:174-183). This variant has been detected in at least one individual at an allele fraction that is suggestive of clonal hematopoiesis, a predictor of TP53 pathogenicity (Ambry internal data; Fortuno C et al. Genet Med. 2022 03;24:673-680). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Genome-Nilou Lab, SCV002582357.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenonot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 25, 2025